These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36071483)

  • 1. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study.
    Cano-Jiménez E; Romero Ortiz AD; Villar A; Rodríguez-Nieto MJ; Ramon A; Armengol S
    Respir Res; 2022 Sep; 23(1):235. PubMed ID: 36071483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
    Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
    Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study).
    Gómez AV; Rodríguez-Nieto MJ; Cano-Jiménez E; Ortiz AR; Morros M; Ramon A; Armengol S
    BMC Pulm Med; 2024 Jul; 24(1):370. PubMed ID: 39080648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
    Yu YF; Macaulay DS; Reichmann WM; Wu EQ; Nathan SD
    Respir Med; 2015 Dec; 109(12):1582-8. PubMed ID: 26607877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
    Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
    Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
    Lassenius MI; Toppila I; Pöntynen N; Kasslin L; Kaunisto J; Kilpeläinen M; Laitinen T
    Eur Clin Respir J; 2020; 7(1):1702618. PubMed ID: 32002175
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
    Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
    J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
    Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
    Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
    Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
    Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
    Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
    Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
    Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis.
    Lee JS; Martin-Schwarze A; Freiheit E; Trzaskoma B; Burg C
    Adv Ther; 2023 Feb; 40(2):691-704. PubMed ID: 36481866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.
    Morell F; Esser D; Lim J; Stowasser S; Villacampa A; Nieves D; Brosa M
    BMC Pulm Med; 2016 Jan; 16():7. PubMed ID: 26758510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
    Bi Y; Rekić D; Paterniti MO; Chen J; Marathe A; Chowdhury BA; Karimi-Shah BA; Wang Y
    J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):55-67. PubMed ID: 32949322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan.
    Cheng SL; Sheu CC; Chian CF; Hsu JY; Kao KC; Hang LW; Lin CH; Fang WF; Wang HC; Perng DW
    Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.